Interestingly, PU + FPR inhibitors-treated HCT 116 had a more prominent decrease in MMP and higher cytochrome C release compared to PU alone treated group implying the possible role played by Anx-A1 in progression of CRC, which brings to the exploration of the second aim discussed in the following section. The gene discussed is FPR1; the disease is colorectal carcinoma.